IL120902A - Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them - Google Patents
Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing themInfo
- Publication number
- IL120902A IL120902A IL12090297A IL12090297A IL120902A IL 120902 A IL120902 A IL 120902A IL 12090297 A IL12090297 A IL 12090297A IL 12090297 A IL12090297 A IL 12090297A IL 120902 A IL120902 A IL 120902A
- Authority
- IL
- Israel
- Prior art keywords
- conjugate
- peg
- ifna
- formula
- polyethylene glycol
- Prior art date
Links
- 229940079322 interferon Drugs 0.000 title claims abstract description 35
- -1 Polyethylene Polymers 0.000 title claims abstract description 4
- 239000004698 Polyethylene Substances 0.000 title claims abstract 3
- 229920000573 polyethylene Polymers 0.000 title claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 47
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 44
- 125000003827 glycol group Chemical group 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 description 31
- 102000014150 Interferons Human genes 0.000 description 31
- 239000003153 chemical reaction reagent Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 29
- 230000001028 anti-proliverative effect Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000840 anti-viral effect Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 102100020870 La-related protein 6 Human genes 0.000 description 6
- 108050008265 La-related protein 6 Proteins 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 239000006167 equilibration buffer Substances 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 230000006320 pegylation Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 241001415846 Procellariidae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000012541 Fractogel® Substances 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229940060205 adagen Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical class ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical class OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- JTESKNWFQRABFY-UHFFFAOYSA-M sodium;tetracosyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCCCCOS([O-])(=O)=O JTESKNWFQRABFY-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1883496P | 1996-05-31 | 1996-05-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL120902A0 IL120902A0 (en) | 1997-09-30 |
| IL120902A true IL120902A (en) | 2004-06-20 |
Family
ID=21790006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12090297A IL120902A (en) | 1996-05-31 | 1997-05-23 | Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them |
Country Status (47)
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| JP2000507917A (ja) | 1995-11-02 | 2000-06-27 | シェーリング コーポレイション | 持続的低用量サイトカイン注入治療 |
| US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US6180096B1 (en) | 1998-03-26 | 2001-01-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| CZ302005B6 (cs) * | 1998-03-26 | 2010-09-01 | Schering Corporation | Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující |
| WO1999055377A2 (fr) * | 1998-04-28 | 1999-11-04 | Applied Research Systems Ars Holding N.V. | Conjugues de polyol-ifn beta |
| ES2172288T3 (es) | 1998-05-15 | 2002-09-16 | Schering Corp | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. |
| ID29285A (id) * | 1998-06-08 | 2001-08-16 | Hoffmann La Roche | PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| IL129299A0 (en) * | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| US6605273B2 (en) | 1999-04-08 | 2003-08-12 | Schering Corporation | Renal cell carcinoma treatment |
| US6362162B1 (en) | 1999-04-08 | 2002-03-26 | Schering Corporation | CML Therapy |
| PT1043026E (pt) | 1999-04-08 | 2005-09-30 | Schering Corp | Terapeutica do melanoma |
| TWI271196B (en) * | 1999-04-08 | 2007-01-21 | Schering Corp | CML therapy |
| US6923966B2 (en) | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6313143B1 (en) * | 1999-12-16 | 2001-11-06 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| CZ20022727A3 (cs) | 2000-01-10 | 2002-11-13 | Maxygen Holdings Ltd | Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek |
| EP1908477A3 (fr) * | 2000-01-24 | 2008-06-11 | Schering Corporation | Combinaison de témozolomide et interféron alpha pégylé pour le traitement du cancer |
| WO2001052882A1 (fr) * | 2000-01-24 | 2001-07-26 | Schering Corporation | Combinaison de temozolomide et d'alpha-interferon pegyle pour le traitement du cancer |
| EP1982732A3 (fr) | 2000-02-11 | 2011-06-08 | Bayer HealthCare LLC | Conjugués de type facteur VII ou VIIA |
| US6476062B2 (en) | 2000-03-30 | 2002-11-05 | Schering Corporation | Chemokine receptor antagonists |
| US6777387B2 (en) | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
| US6756037B2 (en) | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
| EP1282632A1 (fr) | 2000-04-20 | 2003-02-12 | Schering Corporation | Traitement combine de ribavirine-interferon alfa pour eliminer l'arn-vhc decelable chez un patient souffrant d'infections chroniques par l'hepatite c |
| CN100448993C (zh) | 2000-06-30 | 2009-01-07 | 津莫吉尼蒂克斯公司 | 干扰素样蛋白质Zcyto21 |
| EP1400550B1 (fr) * | 2001-01-30 | 2010-06-23 | Kyowa Hakko Kirin Co., Ltd. | Polyalkylene glycols ramifies |
| PL367154A1 (en) | 2001-02-27 | 2005-02-21 | Maxygen Aps | New interferon beta-like molecules |
| DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
| EP1465933B1 (fr) | 2002-01-16 | 2007-08-29 | Biocompatibles UK Limited | Conjugues polymeres |
| KR100888371B1 (ko) * | 2002-01-17 | 2009-03-13 | 동아제약주식회사 | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
| BR0311978A (pt) | 2002-06-21 | 2005-03-22 | Novo Nordisk Healthcare Ag | Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação |
| MXPA05000796A (es) | 2002-07-24 | 2005-04-19 | Hoffmann La Roche | Aditivos de acidos polialquilenglicolicos. |
| US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| ES2214166T1 (es) * | 2002-09-11 | 2004-09-16 | Fresenius Kabi Deutschland Gmbh | Polipeptidos has-ilados, especialmente, eriptropoyetina has-ilada. |
| EP1681303B1 (fr) * | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | Polypeptides HASylés, en particulier érythropoiétine HASylée |
| BR0314107A (pt) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Método de produção de derivados de hidroxialquil amido |
| RU2368619C2 (ru) * | 2002-09-20 | 2009-09-27 | Фармация Корпорейшн | Способ получения соматотропного гормона со сниженным содержанием агрегата его изоформ, способ получения антагониста соматотропного гормона со сниженным содержанием агрегата его изоформ и общим суммарным содержанием трисульфидной примеси и/или дефенилаланиновой примеси |
| AU2003273413A1 (en) | 2002-10-08 | 2004-05-04 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
| NZ540043A (en) * | 2002-11-18 | 2007-11-30 | Maxygen Inc | Isolated or recombinant Interferon-alpha polypeptides and conjugates |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| GB0301014D0 (en) * | 2003-01-16 | 2003-02-19 | Biocompatibles Ltd | Conjugation reactions |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| CA2458085A1 (fr) | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Analyse d'activite transcriptionnelle |
| WO2005014655A2 (fr) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugues d'amidon d'hydroxyalkyle et de proteine |
| EP1673387B1 (fr) | 2003-10-10 | 2010-09-15 | Novo Nordisk A/S | Derives de il-21 |
| ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| SG135176A1 (en) | 2004-02-02 | 2007-09-28 | Ambrx Inc | Modified human four helical bundle polypeptides and their uses |
| CN100355784C (zh) * | 2004-02-12 | 2007-12-19 | 江苏恒瑞医药股份有限公司 | 聚乙二醇修饰α－干扰素1b的制备方法 |
| EA010501B1 (ru) | 2004-03-11 | 2008-10-30 | Фрезениус Каби Дойчланд Гмбх | Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием |
| JP2008507298A (ja) | 2004-05-19 | 2008-03-13 | マキシジェン， インコーポレイテッド | インターフェロンαポリペプチドおよび結合体 |
| CN102603895B (zh) | 2004-06-18 | 2016-09-28 | Ambrx公司 | 新颖抗原结合多肽和其用途 |
| AU2005260664A1 (en) * | 2004-06-30 | 2006-01-12 | Egen Corporation | Pegylated interferon alpha-1b |
| WO2006091231A2 (fr) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle |
| MX2007001663A (es) | 2004-08-12 | 2007-04-10 | Schering Corp | Formulacion de interferon pegilado estable. |
| CN103690936A (zh) | 2004-12-22 | 2014-04-02 | Ambrx公司 | 经修饰的人类生长激素 |
| EP1861125A2 (fr) * | 2005-03-23 | 2007-12-05 | Nektar Therapeutics Al, Corporation | Conjugues d'un fragment de hgh et d'un polymere |
| WO2007044083A2 (fr) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Polypeptides d'interferon-alpha mis au point genetiquement |
| EP1893632B1 (fr) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Reduction et derivation séléctives de proteines facteur vii comprenant au moins une cysteine non native |
| CN101257925A (zh) * | 2005-06-20 | 2008-09-03 | 派普根公司 | 人干扰素α类似物和干扰素τ的低毒长循环的嵌合体 |
| JP4829969B2 (ja) | 2005-08-18 | 2011-12-07 | アンブルックス，インコーポレイテッド | ｔＲＮＡ組成物、およびその使用 |
| JP4261531B2 (ja) | 2005-09-06 | 2009-04-30 | 株式会社Ｎｒｌファーマ | ラクトフェリン複合体及びその製造方法 |
| KR20080079643A (ko) | 2005-11-16 | 2008-09-01 | 암브룩스, 인코포레이티드 | 비-천연 아미노산을 포함하는 방법 및 조성물 |
| CN101002944B (zh) * | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
| CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
| CN101002945B (zh) | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| CA2652333A1 (fr) | 2006-05-16 | 2007-11-22 | Tokyo Metropolitan Organization For Medical Research | Composition pharmaceutique destinee au traitement ou a la prevention d'une infection par le vhc |
| RU2008145084A (ru) | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
| CA2663083A1 (fr) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations |
| CN101541955B (zh) | 2006-09-08 | 2016-09-28 | Ambrx公司 | 用于脊椎动物细胞的杂合抑制tRNA |
| CN1966547B (zh) * | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
| WO2008055666A1 (fr) * | 2006-11-07 | 2008-05-15 | Dsm Ip Assets B.V. | Carbamate, thiocarbamate ou carbamide comprenant une fraction biomoléculaire |
| KR101079993B1 (ko) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
| CN101219219B (zh) | 2007-01-10 | 2013-02-13 | 北京普罗吉生物科技发展有限公司 | 包含血管抑素或其片段的复合物、其制备方法及应用 |
| JP5515224B2 (ja) | 2007-02-28 | 2014-06-11 | 日油株式会社 | 多分岐鎖ポリオキシアルキレン誘導体 |
| BRPI0809583B1 (pt) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo |
| CL2008002399A1 (es) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| WO2009030066A1 (fr) | 2007-09-04 | 2009-03-12 | Biosteed Gene Expression Tech. Co., Ltd. | Interféron alpha 2b modifié par du polyethylèneglycol et procédé de préparation et applications associés |
| PL2196475T3 (pl) | 2007-09-04 | 2012-10-31 | Biosteed Gene Expression Tech Co Ltd | Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie |
| ES2632504T3 (es) | 2007-11-20 | 2017-09-13 | Ambrx, Inc. | Polipéptidos de insulina modificados y sus usos |
| EP2070950A1 (fr) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation |
| EP2245044A2 (fr) * | 2008-01-18 | 2010-11-03 | F. Hoffmann-La Roche AG | Purification de protéines non-glycosylées |
| HRP20191052T1 (hr) * | 2008-02-01 | 2019-11-01 | Ascendis Pharma As | Predlijek koji obuhvaća samocijepajuću poveznicu |
| NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
| BRPI0822530B1 (pt) | 2008-04-03 | 2022-03-22 | Biosteed Gene Expression Tech. Co., Ltd | Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição |
| ES2875426T3 (es) | 2008-04-29 | 2021-11-10 | Ascendis Pharma Endocrinology Div A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| TW201010692A (en) | 2008-06-19 | 2010-03-16 | Public Univ Corp Nagoya City Univ | Pharmaceutical composition for treatment or prevention of hbv infection |
| AU2009268841B2 (en) | 2008-07-08 | 2014-02-06 | Board Of Regents, The University Of Texas System | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS) |
| PE20110426A1 (es) | 2008-07-23 | 2011-07-01 | Ambrx Inc | Polipeptidos g-csf bovinos modificados |
| CN102232085A (zh) | 2008-09-26 | 2011-11-02 | Ambrx公司 | 修饰的动物促红细胞生成素多肽和其用途 |
| PT2337846T (pt) | 2008-09-26 | 2018-04-05 | Ambrx Inc | Vacinas e microrganismos dependentes da replicação de aminoácidos não naturais |
| IT1399351B1 (it) | 2009-06-16 | 2013-04-16 | Fidia Farmaceutici | Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| BR112012014721B1 (pt) | 2009-12-15 | 2022-06-28 | Ascendis Pharma Endocrinology Division A/S | Composições de hormônio do crescimento, seus métodos de fabricação, recipiente e kit |
| JP2013515080A (ja) | 2009-12-21 | 2013-05-02 | アンブルックス，インコーポレイテッド | 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用 |
| WO2011087810A1 (fr) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Polypeptides d'hormone de croissance porcine modifiée et leurs utilisations |
| US9815876B2 (en) | 2010-03-05 | 2017-11-14 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| EP2569331A1 (fr) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptides inhibiteurs de vla4 |
| EP2585065A1 (fr) | 2010-06-24 | 2013-05-01 | Panmed Ltd. | Traitement de maladies associées au virus de l'hépatite c utilisant de l'hydroxychloroquine ou de l'hydroxychloroquine associée à un agent antiviral |
| RU2447083C1 (ru) * | 2010-07-20 | 2012-04-10 | Закрытое Акционерное Общество "Биокад" | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ |
| EP2600898A1 (fr) | 2010-08-05 | 2013-06-12 | F.Hoffmann-La Roche Ag | Protéine de fusion anticorps anti-cmh cytokine antivirale |
| AU2011291943B2 (en) | 2010-08-17 | 2015-01-22 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| WO2012146630A1 (fr) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | Polypeptides acylés en position n-terminale, leurs procédés de préparation et leurs utilisations |
| CN102229667A (zh) * | 2011-06-03 | 2011-11-02 | 北京伟嘉人生物技术有限公司 | 一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用 |
| MX2014000031A (es) | 2011-07-01 | 2014-07-09 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos. |
| PH12014500283A1 (en) | 2011-08-03 | 2014-03-31 | Cytheris | Hcv immunotherapy |
| JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法 |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
| BR112015004022B1 (pt) | 2012-08-31 | 2023-04-25 | Sutro Biopharma, Inc | Aminoácidos modificados compreendendo um grupo azido |
| EA021610B1 (ru) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Жидкое противовирусное лекарственное средство |
| EA022617B1 (ru) * | 2013-03-28 | 2016-02-29 | Илья Александрович МАРКОВ | Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа |
| EA023323B1 (ru) * | 2013-03-28 | 2016-05-31 | Илья Александрович МАРКОВ | Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона |
| ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| US9840493B2 (en) | 2013-10-11 | 2017-12-12 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
| EP2907512A1 (fr) | 2014-02-14 | 2015-08-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Inhibiteurs de MMP-12 en tant qu'agents antiviraux |
| RU2554761C1 (ru) * | 2014-05-13 | 2015-06-27 | Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" | Противоэнтеровирусное и иммуностимулирующее средство |
| SG11201702824UA (en) | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Modified fgf-21 polypeptides and uses thereof |
| SI3215193T1 (sl) | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dozirna shema za pegiliran interferon |
| SMT202100172T1 (it) | 2014-11-18 | 2021-05-07 | Ascendis Pharma Endocrinology Div A/S | Nuovi profarmaci polimerici a base di hgh |
| ES2896971T3 (es) | 2014-11-21 | 2022-02-28 | Ascendis Pharma Endocrinology Div A/S | Formas de administración de hormona del crecimiento de acción prolongada |
| CN108135979A (zh) | 2015-11-03 | 2018-06-08 | 豪夫迈·罗氏有限公司 | Hbv衣壳组装抑制剂和干扰素的组合疗法 |
| CN106749608B (zh) * | 2015-11-18 | 2021-10-15 | 石药集团中奇制药技术（石家庄）有限公司 | 干扰素α缀合物 |
| WO2018087345A1 (fr) | 2016-11-14 | 2018-05-17 | F. Hoffmann-La Roche Ag | Polythérapie comprenant un inhibiteur d'un antigène de hbsag, un analogue nucléosidique ou nucléotidique et un interféron |
| KR102670432B1 (ko) | 2017-02-08 | 2024-05-28 | 브리스톨-마이어스 스큅 컴퍼니 | 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도 |
| RU2678332C1 (ru) | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| SG11202102427XA (en) | 2018-09-11 | 2021-04-29 | Ambrx Inc | Interleukin-2 polypeptide conjugates and their uses |
| AU2019361206A1 (en) | 2018-10-19 | 2021-06-03 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
| CN119455004A (zh) | 2019-02-12 | 2025-02-18 | Ambrx公司 | 包含抗体-tlr激动剂缀合物的组合物、方法和用途 |
| SG11202108735QA (en) | 2019-03-04 | 2021-09-29 | Ascendis Pharma Endocrinology Div A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| CA3174114A1 (fr) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Conjugues polypeptidiques d'interleukine-2 et leurs procedes d'utilisation |
| WO2022040596A1 (fr) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci |
| IL303948A (en) * | 2020-12-23 | 2023-08-01 | Jazz Pharmaceuticals Ireland Ltd | Methods of purifying charge-shielded fusion proteins |
| KR20240004342A (ko) | 2021-04-03 | 2024-01-11 | 암브룩스, 인코포레이티드 | 항-her2 항체-약물 접합체 및 이의 용도 |
| CN120676956A (zh) | 2023-02-09 | 2025-09-19 | 谢彦晖 | 聚乙二醇修饰的白介素2、糖皮质激素和透明质酸用于治疗特应性皮炎 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| WO1984004745A1 (fr) | 1983-05-31 | 1984-12-06 | Takeda Chemical Industries Ltd | Nouveaux polypeptides et leur utilisation |
| US4681848A (en) | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| DE3676670D1 (de) | 1985-06-26 | 1991-02-07 | Cetus Corp | Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5145773A (en) * | 1989-05-25 | 1992-09-08 | Sloan-Kettering Institute For Cancer Research | Method to detect sensitivity to alpha-interferon therapy |
| EP0400472B1 (fr) * | 1989-05-27 | 1996-04-03 | Sumitomo Pharmaceuticals Company, Limited | Procédé pour la préparation de dérivés de polyéthylène glycol et protéine modifiée. |
| US5238915A (en) | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| GB9111967D0 (en) | 1991-06-04 | 1991-07-24 | Erba Carlo Spa | 2,5'-nucleotide analogs as antiviral agents |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| RU2006036C1 (ru) * | 1991-12-27 | 1994-01-15 | Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН | Способ определения антигенов |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| CA2176229C (fr) * | 1993-11-10 | 2003-05-27 | Carl W. Gilbert | Produits de conjugaison ameliores d'un interferon avec un polymere |
| IL112583A0 (en) * | 1994-02-08 | 1995-05-26 | Amgen Inc | Oral delivery of chemically modified proteins |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) * | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| CA2458085A1 (fr) * | 2003-03-21 | 2004-09-21 | F. Hoffmann-La Roche Ag | Analyse d'activite transcriptionnelle |
-
1997
- 1997-04-19 TW TW086105104A patent/TW517067B/zh not_active IP Right Cessation
- 1997-04-23 CA CA002203480A patent/CA2203480C/fr not_active Expired - Lifetime
- 1997-05-07 RS YU17597A patent/RS49533B/sr unknown
- 1997-05-09 TR TR97/00358A patent/TR199700358A3/tr unknown
- 1997-05-12 SG SG1997001485A patent/SG55314A1/en unknown
- 1997-05-14 SA SA97180030A patent/SA97180030B1/ar unknown
- 1997-05-22 DE DE0809996T patent/DE809996T1/de active Pending
- 1997-05-22 DK DK97108261T patent/DK0809996T3/da active
- 1997-05-22 PT PT97108261T patent/PT809996E/pt unknown
- 1997-05-22 DE DE69720320T patent/DE69720320T2/de not_active Expired - Lifetime
- 1997-05-22 SI SI9730506T patent/SI0809996T1/xx unknown
- 1997-05-22 EP EP97108261A patent/EP0809996B1/fr not_active Expired - Lifetime
- 1997-05-22 ES ES97108261T patent/ES2110386T3/es not_active Expired - Lifetime
- 1997-05-22 DE DE2003199018 patent/DE10399018I1/de active Pending
- 1997-05-22 AT AT97108261T patent/ATE235920T1/de active
- 1997-05-23 IL IL12090297A patent/IL120902A/en not_active IP Right Cessation
- 1997-05-26 NZ NZ314903A patent/NZ314903A/xx not_active IP Right Cessation
- 1997-05-26 ZA ZA974583A patent/ZA974583B/xx unknown
- 1997-05-27 TN TNTNSN97091A patent/TNSN97091A1/fr unknown
- 1997-05-27 EG EG46597A patent/EG24292A/xx active
- 1997-05-27 PA PA19978431001A patent/PA8431001A1/es unknown
- 1997-05-28 HR HR970298A patent/HRP970298B1/xx not_active IP Right Cessation
- 1997-05-28 HU HU9700959A patent/HU227992B1/hu unknown
- 1997-05-28 PL PL97320251A patent/PL186949B1/pl unknown
- 1997-05-28 SK SK673-97A patent/SK284458B6/sk not_active IP Right Cessation
- 1997-05-29 MY MYPI97002342A patent/MY117909A/en unknown
- 1997-05-29 AR ARP970102305A patent/AR008378A1/es active IP Right Grant
- 1997-05-29 CN CN97113049A patent/CN1088721C/zh not_active Expired - Lifetime
- 1997-05-29 CO CO97029836A patent/CO4950528A1/es unknown
- 1997-05-29 JP JP9139807A patent/JP2980569B2/ja not_active Expired - Lifetime
- 1997-05-30 KR KR1019970022223A patent/KR100254097B1/ko not_active Expired - Lifetime
- 1997-05-30 IS IS4491A patent/IS1988B/is unknown
- 1997-05-30 AU AU23723/97A patent/AU725195B2/en not_active Expired
- 1997-05-30 CZ CZ19971679A patent/CZ292775B6/cs not_active IP Right Cessation
- 1997-05-30 SV SV1997000049A patent/SV1997000049A/es not_active Application Discontinuation
- 1997-05-30 RU RU97108698/14A patent/RU2180595C2/ru active
- 1997-05-30 OA OA70015A patent/OA10488A/fr unknown
- 1997-05-30 UY UY24572A patent/UY24572A1/es not_active IP Right Cessation
- 1997-05-30 TJ TJ97000465A patent/TJ328B/xx unknown
- 1997-05-30 BG BG101540A patent/BG62273B1/bg unknown
- 1997-05-30 NO NO19972480A patent/NO322964B1/no not_active IP Right Cessation
- 1997-05-30 MA MA24641A patent/MA24193A1/fr unknown
- 1997-05-30 UA UA97052543A patent/UA56989C2/uk unknown
- 1997-06-02 BR BR9703421A patent/BR9703421A/pt not_active IP Right Cessation
-
1998
- 1998-01-30 GR GR970300063T patent/GR970300063T1/el unknown
-
2003
- 2003-02-27 US US10/377,892 patent/US7201897B2/en not_active Expired - Fee Related
- 2003-05-08 NL NL300127C patent/NL300127I2/nl unknown
- 2003-06-25 LU LU91029C patent/LU91029I2/fr unknown
-
2004
- 2004-03-19 CY CY0400021A patent/CY2433B1/xx unknown
-
2005
- 2005-04-05 CY CY200500006C patent/CY2005006I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2203480C (fr) | Conjugues de l'interferon | |
| AU739359B2 (en) | Improved interferon polymer conjugates | |
| CA2312976C (fr) | Compositions comprenant des conjugues de polymere de proteines lies a l'histidine | |
| US20060029573A1 (en) | Pegylated interferon alpha-1b | |
| JP2003155299A (ja) | Ｎ末端化学修飾タンパク質組成物および方法 | |
| HUT75533A (en) | Improved interferon polymer conjugates | |
| KR20020007296A (ko) | Ｇｃｓｆ 결합체 | |
| RU2447083C1 (ru) | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ | |
| JP5458416B2 (ja) | 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用 | |
| HK1005225B (en) | Interferon conjugates | |
| MXPA97004012A (en) | Conjugados de interfe | |
| KR100888371B1 (ko) | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| EXTP | Application for extension order is pending | ||
| KB | Patent renewed | ||
| PEL | Intention of commissioner to extend period of protection | ||
| EXTG | Extension of patent term granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) | ||
| EXP | Patent expired |